Lemborexant
- TRADE NAME: Dayvigo (Eisai)
- INDICATIONS: Adult patients with insomnia
- CLASS: Orexin receptor antagonist
- HALF-LIFE: 17–19 hours
FDA APPROVAL DATE: 12/20/2019
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Bosentan, Carbamazepine, Chlorzoxazone, Clarithromycin, CYP3A inhibitors and inducers, Efavirenz, Etravirine, Fluconazole, Itraconazole, Modafinil, Ranitidine, Rifampin, St John's Wort, Verapamil
No available data in pregnant women to evaluate for drug-associated risks of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Impairs alertness and motor coordination including morning impairment. Risk increases with dose and if used with other central nervous system depressants.
Please login to see the rest of this drug profile
CENTRAL NERVOUS SYSTEM.
GENITOURINARY.
RESPIRATORY.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric